Ipsen’s Partner Lexicon Pharmaceuticals Announces That FDA Approves Lexicon Drug Xermelo™ (Telotristat ethyl) 250 mg as First and Only Oral Treatment for Carcinoid Syndrome Diarrhea in Cancer Patients with Metastatic Neuroendocrine Tumors.
This article or press release has no online content. Please download the associated documents for more information.
You are now leaving the Ipsen Group section. If you would like to visit an affiliate section, please click Continue. The information provided on this section may not necessarily be applicable to the Ipsen Group.